Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
N07XX14
|
| gptkbp:CASNumber |
1093845-63-2
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Biohaven_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C9H9BrN2O2
|
| gptkbp:hasTherapeuticUse |
gptkb:Alzheimer's_disease
gptkb:obsessive-compulsive_disorder neurological disorders spinocerebellar ataxia |
| https://www.w3.org/2000/01/rdf-schema#label |
Troriluzole
|
| gptkbp:isUnderInvestigationFor |
gptkb:Alzheimer's_disease
gptkb:obsessive-compulsive_disorder spinocerebellar ataxia |
| gptkbp:IUPACName |
5-[(trifluoromethoxy)benzylamino]benzothiazol-2-amine
|
| gptkbp:prodrugOf |
gptkb:riluzole
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
glutamate system
|
| gptkbp:bfsParent |
gptkb:Biohaven_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|